• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

An alternative approach to the optimal design of an LD50 bioassay.

作者信息

Markus R A, Frank J, Groshen S, Azen S P

机构信息

Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles 90033, USA.

出版信息

Stat Med. 1995 Apr 30;14(8):841-52. doi: 10.1002/sim.4780140812.

DOI:10.1002/sim.4780140812
PMID:7644863
Abstract

In this paper we propose an alternative approach to the optimal design of an LD50 bioassay. We adopt a Bayesian approach to make use of prior information about the location and scale parameters of the tolerance distribution function to select the design parameters (number of doses, total number of animals, centre of doses, space between doses), and we adopt a frequentist approach using the Spearman-Karber statistic to estimate the LD50. We define the optimal design as the one that produces the minimum expected mean squared error E(MSE) with respect to the joint prior distribution of the parameters of the tolerance distribution. For the design parameters investigated, we found: (i) the shape of the E(MSE) is relatively smooth and continuous, the magnitude of which is influenced by the underlying tolerance distribution; (ii) the amount of prior information about the location and scale parameters independently and jointly affect the optimal design; and (iii) as the amount of prior information decreases, one requires more doses and/or animals. Finally, we show the proposed method is robust for an incorrectly assumed tolerance distribution function.

摘要

相似文献

1
An alternative approach to the optimal design of an LD50 bioassay.
Stat Med. 1995 Apr 30;14(8):841-52. doi: 10.1002/sim.4780140812.
2
A curve similarity approach to parallelism testing in bioassay.曲线相似性方法在生物测定中的平行性检验。
J Biopharm Stat. 2020 Jul 3;30(4):721-733. doi: 10.1080/10543406.2020.1730875. Epub 2020 Mar 12.
3
Interval estimators of relative potency in toxicology and radiation countermeasure studies: comparing methods and experimental designs.毒理学和辐射对策研究中相对效力的区间估计:方法与实验设计比较
J Biopharm Stat. 2019;29(2):348-358. doi: 10.1080/10543406.2018.1535500. Epub 2018 Oct 23.
4
A fast and reliable test for parallelism in bioassay.生物测定中一种快速可靠的平行性检验方法。
J Biopharm Stat. 2019;29(6):1011-1023. doi: 10.1080/10543406.2019.1572615. Epub 2019 Feb 4.
5
Sequential method of estimating the LD50 using a modified up-and-down rule.使用改良上下法估计半数致死剂量(LD50)的序贯方法。
J Biopharm Stat. 1994 Mar;4(1):19-30. doi: 10.1080/10543409408835069.
6
A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.一种用于确定I/II期临床试验最佳生物学剂量的稳健两阶段设计。
Stat Med. 2017 Jan 15;36(1):27-42. doi: 10.1002/sim.7082. Epub 2016 Aug 18.
7
A Bayesian-frequentist two-stage single-arm phase II clinical trial design.贝叶斯-频率派两阶段单臂二期临床试验设计。
Stat Med. 2012 Aug 30;31(19):2055-67. doi: 10.1002/sim.5330. Epub 2012 Mar 13.
8
Robustness of choice of number of doses for maximum likelihood estimation of the ED(50) in bioassay.生物测定中用于半数有效剂量(ED(50))最大似然估计的剂量数选择的稳健性。
Stat Med. 2002 Aug 15;21(15):2215-23. doi: 10.1002/sim.1204.
9
Bayesian designs and the control of frequentist characteristics: a practical solution.贝叶斯设计与频率论特征的控制:一种实用解决方案。
Biometrics. 2015 Mar;71(1):218-226. doi: 10.1111/biom.12226. Epub 2014 Sep 5.
10
Outlier robust nonlinear mixed model estimation.异常值稳健非线性混合模型估计
Stat Med. 2015 Apr 15;34(8):1304-16. doi: 10.1002/sim.6406. Epub 2015 Jan 8.

引用本文的文献

1
Human PrP E219K: a new and promising substrate for robust RT-QuIC amplification of human prions with potential for strain discrimination.人源PrP E219K:一种用于人朊病毒高效RT-QuIC扩增的新型且有前景的底物,具有区分毒株的潜力。
Microbiol Spectr. 2025 Jul 10:e0029225. doi: 10.1128/spectrum.00292-25.
2
Isolation, identification and characteristics of from diseased rainbow trout ().患病虹鳟鱼中[具体微生物名称未给出]的分离、鉴定及特性研究
Front Microbiol. 2025 Jan 7;15:1499126. doi: 10.3389/fmicb.2024.1499126. eCollection 2024.
3
BSE risk posed by ruminant collagen and gelatine derived from bones.
源自骨头的反刍动物胶原蛋白和明胶所带来的牛海绵状脑病风险。
EFSA J. 2024 Jul 16;22(7):e8883. doi: 10.2903/j.efsa.2024.8883. eCollection 2024 Jul.
4
Prion potentiation after life-long dormancy in mice devoid of PrP.在缺乏朊病毒蛋白(PrP)的小鼠中终身休眠后的朊病毒增强作用。
Brain Commun. 2021 Apr 28;3(2):fcab092. doi: 10.1093/braincomms/fcab092. eCollection 2021.
5
Wide distribution of prion infectivity in the peripheral tissues of vCJD and sCJD patients.变异性克雅氏病和散发型克雅氏病患者外周组织中朊病毒感染性的广泛分布。
Acta Neuropathol. 2021 Mar;141(3):383-397. doi: 10.1007/s00401-021-02270-x. Epub 2021 Feb 2.
6
Prions from Sporadic Creutzfeldt-Jakob Disease Patients Propagate as Strain Mixtures.散发性克雅氏病患者的朊病毒以毒株混合物的形式传播。
mBio. 2020 Jun 16;11(3):e00393-20. doi: 10.1128/mBio.00393-20.
7
PrP expression level and sensitivity to prion infection.朊病毒蛋白表达水平与朊病毒感染敏感性。
J Virol. 2014 May;88(10):5870-2. doi: 10.1128/JVI.00369-14. Epub 2014 Feb 26.
8
Detection of infectivity in blood of persons with variant and sporadic Creutzfeldt-Jakob disease.变异型和散发性克雅氏病患者血液中的感染性检测。
Emerg Infect Dis. 2014 Jan;20(1):114-7. doi: 10.3201/eid2001.130353.
9
Highly efficient prion transmission by blood transfusion.高效输血传播朊病毒。
PLoS Pathog. 2012;8(6):e1002782. doi: 10.1371/journal.ppat.1002782. Epub 2012 Jun 21.
10
Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: isolation, purification and neutralization efficacy.鸡卵黄来源的抗志贺毒素 2B 亚单位抗体:分离、纯化和中和效力。
Toxicon. 2011 Sep 15;58(4):380-8. doi: 10.1016/j.toxicon.2011.07.009. Epub 2011 Jul 22.